DK1007080T3 - Formulering til vedvarende frigivelse af peptidagonister og analoger af GnRH - Google Patents

Formulering til vedvarende frigivelse af peptidagonister og analoger af GnRH

Info

Publication number
DK1007080T3
DK1007080T3 DK97936524T DK97936524T DK1007080T3 DK 1007080 T3 DK1007080 T3 DK 1007080T3 DK 97936524 T DK97936524 T DK 97936524T DK 97936524 T DK97936524 T DK 97936524T DK 1007080 T3 DK1007080 T3 DK 1007080T3
Authority
DK
Denmark
Prior art keywords
formulation
sustained release
gnrh
analogue
analogues
Prior art date
Application number
DK97936524T
Other languages
Danish (da)
English (en)
Inventor
Timothy Elliot Trigg
John Desmond Walsh
Paul Adam Schober
Original Assignee
Peptech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO2035A external-priority patent/AUPO203596A0/en
Priority claimed from AUPO4107A external-priority patent/AUPO410796A0/en
Application filed by Peptech Ltd filed Critical Peptech Ltd
Application granted granted Critical
Publication of DK1007080T3 publication Critical patent/DK1007080T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK97936524T 1996-08-30 1997-09-01 Formulering til vedvarende frigivelse af peptidagonister og analoger af GnRH DK1007080T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO2035A AUPO203596A0 (en) 1996-08-30 1996-08-30 Hormone therapy
AUPO4107A AUPO410796A0 (en) 1996-12-06 1996-12-06 Method of treating benign prostatic hyperplasia
PCT/AU1997/000560 WO1998008533A1 (en) 1996-08-30 1997-09-01 Sustained peptide-release formulation

Publications (1)

Publication Number Publication Date
DK1007080T3 true DK1007080T3 (da) 2007-07-30

Family

ID=25645254

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97936524T DK1007080T3 (da) 1996-08-30 1997-09-01 Formulering til vedvarende frigivelse af peptidagonister og analoger af GnRH

Country Status (12)

Country Link
US (3) US6337318B1 (de)
EP (1) EP1007080B1 (de)
JP (1) JP3860841B2 (de)
CN (1) CN1216636C (de)
AT (1) ATE359805T1 (de)
CA (1) CA2264562C (de)
DE (1) DE69737635T2 (de)
DK (1) DK1007080T3 (de)
ES (1) ES2285737T3 (de)
HK (1) HK1022275A1 (de)
NZ (1) NZ334236A (de)
WO (1) WO1998008533A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334236A (en) * 1996-08-30 2000-06-23 Peptech Ltd Composition comprising GnRH, lecithin and stearin
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
CA2336879C (en) * 1998-07-20 2010-06-01 Peptech Limited Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients
JP2004512369A (ja) * 2000-10-30 2004-04-22 ユニバーシティ・オブ・チューリッヒ 尿失禁の治療のためのｇｎｒｈアナログ
US7776310B2 (en) * 2000-11-16 2010-08-17 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US20030186892A1 (en) * 2002-03-28 2003-10-02 Rajneesh Taneja Enhancement of endogenous gonadotropin production
CN1688696A (zh) * 2002-09-18 2005-10-26 蒙特利尔大学医疗中心 Ghrh类似物
MXPA05003318A (es) * 2002-09-27 2005-09-12 Zentaris Gmbh Forma de administracion para peptidos farmaceuticamente activos con liberacion sostenida y metodo para la produccion de los mismos.
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
US8062652B2 (en) * 2004-06-17 2011-11-22 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating precocious puberty
WO2006071208A1 (en) * 2004-12-23 2006-07-06 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of a gnrh
JP4584331B2 (ja) * 2005-03-11 2010-11-17 インデバス ファーマシューティカルズ、インク． オクトレオチドの放出制御製剤
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8882747B2 (en) * 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2139447A2 (de) * 2007-03-20 2010-01-06 Harold Brem Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
CA2683517A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
RU2521291C2 (ru) * 2008-06-25 2014-06-27 Эндо Фармасьютикалз Солюшнз Инк. Имплантат октреотида, содержащий высвобождающее вещество
US8071537B2 (en) * 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
AU2019275409B2 (en) 2018-05-24 2024-08-15 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
CN111971026A (zh) 2018-05-24 2020-11-20 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
KR102249104B1 (ko) * 2019-04-30 2021-05-07 (주)인벤티지랩 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법
WO2024003291A1 (en) 2022-06-30 2024-01-04 Virbac Deslorelin use in chemical castration of a non-human mammal related to pk/pd interaction

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256737A (en) * 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
IT1191608B (it) * 1985-02-01 1988-03-23 Zambon Spa Composizione farmaceutica e forme farmaceutiche che la contengono
JPH0662441B2 (ja) 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
IT1213464B (it) * 1986-07-25 1989-12-20 Riccardo Casero Forma farmaceutica per la somministrazione enterica di acido etodolico o di suoi sali, in miscela con eccipienti.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5039660A (en) * 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
US5256649A (en) * 1989-05-23 1993-10-26 Elf Sanofi Cosmetic composition against aging of the skin
US5180434A (en) 1991-03-11 1993-01-19 United Solar Systems Corporation Interfacial plasma bars for photovoltaic deposition apparatus
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
WO1993007833A1 (en) 1991-10-21 1993-04-29 Peptide Technology Limited Biocompatible implant for the timing of ovulation in mares
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
KR950007873A (ko) 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
JPH09507233A (ja) * 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US6136781A (en) * 1995-04-28 2000-10-24 Takeda Chemical Industries, Ltd. LH-RH receptor antagonists
AUPN366795A0 (en) * 1995-06-20 1995-07-13 Peptide Technology Limited Formulation for preventing reproductive function
NZ334236A (en) * 1996-08-30 2000-06-23 Peptech Ltd Composition comprising GnRH, lecithin and stearin

Also Published As

Publication number Publication date
JP3860841B2 (ja) 2006-12-20
US20040180832A1 (en) 2004-09-16
CN1216636C (zh) 2005-08-31
ES2285737T3 (es) 2007-11-16
EP1007080B1 (de) 2007-04-18
ATE359805T1 (de) 2007-05-15
US7309689B2 (en) 2007-12-18
CA2264562A1 (en) 1998-03-05
EP1007080A1 (de) 2000-06-14
NZ334236A (en) 2000-06-23
US6337318B1 (en) 2002-01-08
US6777386B2 (en) 2004-08-17
CN1228707A (zh) 1999-09-15
EP1007080A4 (de) 2006-01-18
WO1998008533A1 (en) 1998-03-05
US20020052320A1 (en) 2002-05-02
HK1022275A1 (en) 2000-08-04
DE69737635D1 (de) 2007-05-31
DE69737635T2 (de) 2008-01-03
JP2000517307A (ja) 2000-12-26
CA2264562C (en) 2012-01-03

Similar Documents

Publication Publication Date Title
DK1007080T3 (da) Formulering til vedvarende frigivelse af peptidagonister og analoger af GnRH
NZ234414A (en) A method of prophylaxis and/or treatment of benign prostatic hyperplasia (bph)
ATE215081T1 (de) Gonadotropin releasing hormon- antagonisten
MX9502034A (es) Formulacion estable, liofilizada, que comprende una proteina y equipo de dosificacion.
MXPA03004883A (es) Metodo para la estabilizacion de biomoleculas (por ejemplo, insulina) en formulaciones liquidas.
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
TR199701071T2 (xx) Aktif madde ulaştırmaya mahsus bileşikler ve terkipler.
WO2000008015A3 (en) Fsh mimetics for the treatment of infertility
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
TW347339B (en) Oral delivery of discrete units
DK1021204T3 (da) Bioadhæsive præparater og fremgangsmåder til topisk administration af aktive midler
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
EP0646007A4 (de)
ATE248832T1 (de) Antagonisten des gonadotropin freisetzenden hormons
WO2002043706A3 (en) Prolamin-based sustained-release compositions and delayed-onset compositions
DK1210951T3 (da) Præparat indeholdende östrogen-agonister/antagonister og testosteron til behandling af et fald i niveauet af hormonet testosteron
SE9604593D0 (sv) Antimicrobially active polypeptides
GR20020100365A (el) Ιατρικο εργαλειο
DK0917460T3 (da) Cyclosporin-formulering
DK0871467T3 (da) Ny formulering til afgivelse af peptid
AU3630297A (en) Galanin
DE69936638D1 (de) Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
BR0317119A (pt) Agente antitumor, inibidor de proliferação celular, e, análogo de 3-fenil-cinolina